Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Michael Cogburn

Dermatology Arden, NC Medical Doctor

NPI 1912972811 CMS profile 131657

78 Long Shoals Rd, Arden, NC 28704

Open in the dashboard

General payments

$21,263

212 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Michael Cogburn of Arden, NC is reported in the CMS Open Payments database as having received $21,263 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $383 13
2022 General $187 6
2021 General $4,193 35
2020 General $4,164 65
2019 General $12,336 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Cogburn
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Michael Cogburn were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Michael Cogburn Dermatology median Middle half National median
2019 $12,336 $454 $129–$1,240 $163
2020 $4,164 $235 $81–$756 $114
2021 $4,193 $377 $108–$1,108 $132
2022 $187 $514 $143–$1,391 $149
2023 $383 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Galderma Laboratories, L.P. $16,383 31 payments
  2. Merz North America, Inc. $1,464 6 payments
  3. Janssen Biotech, Inc. $542 28 payments
  4. AbbVie, Inc. $443 23 payments
  5. Sun Pharmaceutical Industries Inc. $398 16 payments
  6. Genzyme Corporation $289 15 payments
  7. Lilly USA, LLC $230 11 payments
  8. Novartis Pharmaceuticals Corporation $168 11 payments
  9. Amgen Inc. $147 8 payments
  10. Genentech USA, Inc. $134 8 payments
  11. Other $1,064 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,150 6 payments
  2. Food and Beverage $3,692 193 payments
  3. Travel and Lodging $2,117 9 payments
  4. Education $304 4 payments
Products named General payments · program years 2019–2023
  1. TREMFYA $473 13 payments
  2. HUMIRA $386 20 payments
  3. DUPIXENT $275 13 payments
  4. STELARA $273 23 payments
  5. TALTZ $230 11 payments
  6. SKYRIZI $228 13 payments
  7. SIMPONI ARIA $194 16 payments
  8. REMICADE $194 16 payments
  9. SIMPONI $194 16 payments
  10. ILUMYA $178 6 payments
  11. Other $2,385 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

774

Median for Dermatology: 534

Drug cost

$77,025

Median for Dermatology: $67,151

Branded share of claims

9.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 17 $63,050
Dutasteride Generic 100 $3,016
Ketoconazole Generic 160 $2,044
Doxycycline Hyclate Generic 84 $1,613
Fluorouracil Generic 18 $1,555
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 46 $1,243
Finasteride Generic 165 $1,158
Metronidazole Generic 18 $1,041
Minoxidil Generic 55 $707
Triamcinolone Acetonide Generic 23 $344

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$11,043

Of which drugs: $25

Medicare patients

155

Average age 78

Services billed

573

74 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 41%
Chronic kidney disease 23%
Ischemic heart disease 19%
Cancer 19%
Atrial fibrillation 18%
Diabetes 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 24 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record